However, despite these advances, immunotherapy has shown limited efficacy in hormone receptor-positive (HR+) breast cancers, likely due to their lower tumor mutational burden and immunosuppressive microenvironment [50,51,52]. This evidence concerns the gene NR4A1 and breast carcinoma.